Dendreon Corp. to publish results for Neuvenge
Shares of Dendreon Corp. (Nasdaq: DNDN) are trading higher ahead of the opening bell this morning, after the biotechnology company said it published promising phase I clinical data for its oncology drug Neuvenge.
Neuvenge has been proposed as a treatment for a type of breast cancer known as HER2/neu.
Dendreon is expected to publish its data in the Aug. 20 edition of the Journal of Clinical Oncology.
Shares of Dendreon are up 9.97%, or $0.73, to $8.05 in pre-market trading.
